Evidence method
Level · gp.fundamentals.debt_to_revenue
0.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ABUS · Dec 31, 2024
Arbutus Biopharma Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001447028-25-000083General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.95% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-1050.88% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-65.98% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-1236.74% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
875.66% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
145.62% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 0.00%
- Current
- 2.95%
- Delta
- 2.95%
- Previous
- -1548.62%
- Current
- -1050.88%
- Delta
- 497.74%
- Previous
- -71.25%
- Current
- -65.98%
- Delta
- 5.27%
- Previous
- -1601.19%
- Current
- -1236.74%
- Delta
- 364.46%
- Previous
- 1065.94%
- Current
- 875.66%
- Delta
- -190.28%
- Previous
- 161.31%
- Current
- 145.62%
- Delta
- -15.70%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ABUS Fundamental State →Transitioned To · ABUS Fundamental State →Transitioned To · ABUS CAPEX_INTENSITY_INCREASED →Transitioned To · ABUS CASH_GENERATION_INCREASED →Transitioned To · ABUS GROWTH_INCREASED →Transitioned To · ABUS PROFITABILITY_INCREASED →Transitioned To · ABUS R_AND_D_INTENSITY_DECREASED →Transitioned To · ABUS SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.